Home › Non-Small Cell Lung Cancer › Maine
Pag-aaral pangklinika para sa Non-Small Cell Lung Cancer sa Maine
16 pag-aaral para sa Non-Small Cell Lung Cancer ang naghahanap ng mga kalahok sa mga site sa Maine.
Mga Lungsod sa Maine
- West Scarborough7 pag-aaral
- South Portland7 pag-aaral
- Bangor5 pag-aaral
- Sanford4 pag-aaral
- South Portland Gardens4 pag-aaral
Opisyal na teksto ng pag-aaral (English)
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- at 5 pa
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT04267848A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
- MaineHealth Coastal Cancer Treatment Center, Bath
- MaineHealth Cancer Care and IV Therapy - Brunswick, Brunswick
- MaineHealth Maine Medical Center - Portland, Portland
- at 3 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT07293247A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)
- New England Cancer Specialists ( Site 0139), Westbrook
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT07190248Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Maine Medical Center- Scarborough, Scarborough
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06498635A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
- New England Cancer Specialists ( Site 0095), Westbrook
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06312137This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
- Maine Medical Center, Portland
- MaineHealth Cancer Care and Blood Disorders Scarborough, Scarborough
- MaineHealth Cancer Care and IV Therapy - South Portland, South Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06758401Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥ 50% (MK-2870-007)
- New England Cancer Specialists ( Site 0143), Westbrook
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06170788Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer
- New England Cancer Specialists, Westbrook
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 24, 2026 · NCT06890598A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
- Research Site, Scarborough
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 18, 2026 · NCT06692738Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations
- Research Site, South Portland
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07291037Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Hun 3, 2026 · NCT05642572Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 6, 2026 · NCT06116682Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- Lafayette Family Cancer Center-EMMC, Brewer
Nagre-recruitPhase 2
18 Minutes · Lahat ng kasarian · Na-update May 5, 2026 · NCT06031688Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- Lafayette Family Cancer Center-EMMC, Brewer
- at 5 pa
Nagre-recruitPhase 2/3
Edad 18 pataas · Lahat ng kasarian · Na-update May 5, 2026 · NCT06616584Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics
- Harold Alfond Center for Cancer Care, Augusta
- MaineHealth Waldo Hospital, Belfast
- MaineHealth Maine Medical Center - Biddeford, Biddeford
- at 7 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 17, 2026 · NCT06418204SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Scarborough
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Okt 28, 2025 · NCT03452774Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.